[250 Pages Report] The global Point-of-Care Cholesterol Monitoring Device Market was valued at US$ 428.8 Mn in 2021 and is expected to reach US$ 514.7 Mn by 2028, finds Future Market Insights (FMI) in a recent market survey.
Growing prevalence of target diseases like diabetes, cardiovascular diseases, and dyslipidemia is expected to be the primary factors driving the point-of-care cholesterol monitoring device market. Rising number of obesity and cardiovascular diseases leads to high blood cholesterol and lipoproteins levels, which increases the cholesterol testing requirement leading to growth of the market.
In addition, higher levels of cholesterol leads to buildup of cholesterol, fats and other substances on and around the artery walls, which is known as atherosclerosis. This further leads to conditions like stroke and heart attack, thus, increasing the demand for point-of-care cholesterol testing.
Point-of-care cholesterol monitoring device market holds nearly 5.6% market value share of the Diagnostics Market, which is around US$ 7.6 Bn in 2021. The adoption of these point-of-care devices is an economical way, it aids in early diagnosis and reduces the risk of further complications. Thus, the demand for point-of-care cholesterol monitoring kits and device is increasing nowadays.
Moreover, major players in the market are focusing on introduction of new technologically advanced testing kits and devices in order to increase their product portfolio.
For instance, in May 2021 DiaSys announced the availability of LDL-c direct FS, a new homogenous assay for direct determination of LDL-cholesterol (LDL-C).
Driven by this, sales of point-of-care cholesterol monitoring devices are expected to rise at a 2.6% CAGR through 2028.
Point-of-care Cholesterol Monitoring Device Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 440.6 Million |
| Market Value 2028 | USD 514.7 Billion |
| CAGR 2022-2028 | 2.6% |
| Key Players | The key players are F. Hoffmann-La; Roche Ltd.; Abbott Laboratories; Abaxis, Inc. (Sub of Zoetis Inc.); DiaSys Diagnostic Systems GmbH; ACON Laboratories; PTS Diagnostics; Bioptik Technology, Inc.; SD; Biosensor, Inc.; Jant Pharmacal Corporation, Inc.; Nova Biomedical Corporation.; Beckman Coulter Inc. (Sub of Danaher Corporation) and SAMSUNG HEALTH CARE; Inc. |
| Share of Top 5 Countries | 54.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 2.61% |
| H1, 2022 Projected | 2.62% |
| H1, 2022 Outlook | 2.52% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 10 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 9 ↓ |
The point-of-care cholesterol monitoring device market is subject to influence by rise in patient base with chronic disorders and technological developments in accordance with impact of macro and industry factors. As per the comparative analysis by Future Market Insights for market growth rate in 2022, a decreased value of 09 Basis Point Share (BPS) is expected in H1-2022 (O), when compared with H1-2021.
This owes to the relevance of the overall point-of-care diagnostics market as a whole in its nascent stages in developing regions, such as India. H1-2022 outlook period in comparison to H1-2022 projected period showed a negative growth in terms of Basis Point Share by 10 BPS.
Some factors involved in the increase of BPS include the rise in geriatric population having high level of High Density Lipoproteins (HDL) across the globe. Key players have been incorporating strategies of acquiring emerging players to strengthen their manufacturing facilities, as well increasing their investment in R&D in order to develop novel therapies.
Additionally, there has been rise in cholesterol testing at home and also increasing preference towards portable cholesterol detection devices.
Sales of point-of-care cholesterol monitoring device grew at a CAGR of 2.3% between 2013 and 2021.
Rising incidences of cardiovascular diseases and complications due to high cholesterol among the population is triggering the growth of the global point of care cholesterol monitoring device market. Also, the number of deaths because of cardiovascular diseases, and mortality because of the risk factors like smoking, excessive alcohol consumption, hyperlipidemia, hypercholesterolemia and obesity are rising globally.
As a result, there is growing awareness among the people regarding the benefits of the monitoring devices. In recent years, it is witnessed that governments around the world are taking initiatives to raise awareness associated to health problems. This, in turn, is expected to lead to the development of the market.
Moreover, the growing geriatric population is another factor driving the demand for the point-of-care cholesterol monitoring device market. The increasing old aged population is more prone to higher cholesterol level which is increasing the cholesterol related problems such as cardiovascular diseases. Therefore, the cholesterol testing products are increasing in the market for the forecast period.
In addition, advancements and development of smart & improved point of care cholesterol monitoring devices are expected to be the key factors driving the growth of the global market.
Considering this, FMI expects the global point-of-care cholesterol monitoring device market to grow at a CAGR of 2.6% through 2028.
Principal Consultant
The inaccurate and less reliable results obtained from point of care testing devices is the major factor limiting the growth of the global market. Point of care testing might be helpful in serious situations demanding rapid test results for clinical assessment. However, there are various limitations associated with point of care testing, primarily associated to quality assurance.
The tests carried out in laboratories are performed by trained professionals and ensure accurate results while point of care testing is usually done by untrained professionals as well as patients themselves. Hence, this may result in fluctuation of results due to less accuracy while performing the test, which in turn hampers the market growth.
In addition, stringent regulatory scenarios for new device approval is another factor that is challenging the growth of the market. Various amendments have been made by the regulatory bodies in the recent years to deal with the lack of standardization in device portfolio, which leads to long time period in product approvals, in turn hindering the point-of-care cholesterol monitoring device market.
Similar to other markets, negative effects of the COVID-19 crisis posed several challenges to the development of the diabetes point-of-care cholesterol monitoring device market also. Transportation restrictions and social distancing norms enforced by governments resulted into a shortage of raw materials and workers. This subsequently led to disruption of manufacturing activities through the initial stages of the pandemic.
Numerous international administrations issued health advisories to contain the spread of pandemic. Various initiatives undertaken to increase awareness by these organizations are anticipated to boost the market’s growth during the pandemic crisis. For example, the International Diabetes Federation has indicated that diabetic patients are more susceptible to becoming seriously ill if infected by the virus. Therefore, increasing health awareness and the association of COVID-19 with diabetes is expected to add to the growth of the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The U.S. is estimated to account for around 86.5% of the North America point-of-care cholesterol monitoring device market in 2022.
The rising incidence of cardiovascular disease and growing prevalence of high cholesterol increases the demand for the market. As per the data published by the CDC (Centers for Disease Control & Prevention), it was projected that approximately 34.2 million of the population were suffering from diabetes in the U.S. in 2020. Key manufacturers of point of care cholesterol monitoring devices in the market are focusing on increasing their portfolio by adding new product features to strengthen their position in the U.S.
Germany is estimated to account for 23.8% of the Europe Point-of-care Cholesterol Monitoring Device market in Europe in 2022.
The growth of the market in Germany is due to the initiatives undertaken by the government concerning to the expansion of healthcare infrastructure and, and presence of favorable regulations together with the high disease occurrence levels in the country. For instance, about 10% of the people in Germany suffer from diabetes, out of which 98% accounts for type 2 diabetes. Point-of-care monitoring is extensively used in developed nations due to better reimbursement policies and high awareness as compared to the emerging countries.
The Point-of-care Cholesterol Monitoring Device market in China is estimated to be worth US$ 38.2 Mn in 2022 in the global market.
The primary factors boosting the growth of the market include increasing technological advancement in monitoring devices together with growing adoption of inorganic growth strategies such as agreements and collaborations to manufacture novel devices. Moreover, increasing prevalence of diabetes is another factor supporting the development of the market in China.
Demand for Point-of-care Cholesterol Monitoring Device in India is expected to rise at around 3.0% CAGR over the forecast period.
The growing geriatric population and the increased awareness regarding cholesterol monitoring are some of the major factors that will lead the market development in India. The increasing old aged population is more prone to higher cholesterol level which is increasing the cholesterol related problems such as cardiovascular diseases.
As per the United Nations, report, there were above 138 million persons over 65 years or over of age in India in 2020. This count is expected to almost double by 2050.
By Product, the testing kits segment is anticipated to hold the maximum share of 63.9% in 2022, expanding at rate of nearly 2.4% during the forecast period.
The segment is expected to further gain traction, owing to increasing adoption of point-of-care testing, availability of rapid testing kits and increased awareness regarding cholesterol monitoring.
The major benefit of point-of-care testing kits is that it does not need any clinical laboratory personnel to perform the test and the results are obtained rapidly. This rapid results can help in determination of the course of the treatment in case of emergency. These advantages of testing kits is anticipated to boost the demand for this segment.
In addition, several technological advancements in these testing kits such as the introduction of home testing kits is expected to add to the growth of the segment.
By technology, reflectance photometry segment will lead the market and is projected to account for 51.6% of the total market revenue share in 2022.
The benefits offered by reflectance photometry over other techniques is leading the segment growth. There are several advantages when the testing is done nearer to the patient rather than far away in a laboratory. In reflectance photometry just a small amount of blood is applied on a strip, then the plasma is removed and the strip is dissolved in the reagents, which results into coloration of the strip, indicating the result by showing the intensity. Hence, this is a rapid technique for cholesterol determination and is widely used.
In terms of application, atherosclerosis segment in projected to account for 32.3% of the total market share in 2022. The rising cases of atherosclerosis is the primary factor leading its rising market share.
Atherosclerosis is the accumulation of cholesterol, fats and other substances on the walls of the arteries. This leads to increase in risk of stroke and heart attack due to decrease in the blood flow to the heart muscles because of the narrowing of the arteries. Thus, the use of point of care cholesterol devices for monitoring of arthrosclerosis cases is leading to growth of the atherosclerosis segment among all applications.
By end user, the diagnostics centers & laboratory segment is anticipated to hold the maximum share of 33.7% in 2022, expanding at rapid rate of 2.3% CAGR during the forecast period.
The segment is growing owing to the well-established infrastructure, installation of technologically advanced analysis equipment and rising number of diagnostic centers and laboratories. In addition, growing awareness regarding early diagnosis of disease and increasing prevalence of cardiovascular diseases are some other factors driving the demand for the segment.
Companies operating in the point-of-care cholesterol monitoring device market are consolidated by nature, with a presence of few players holding major share. These players are involved in a number of strategic alliances. The product launch and acquisition accelerates the manufacturer’s strategy to capitalize on the market share and capture the significant share of market. Some of the recent instances include:
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | USD Million for Value |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, South Africa |
| Key Segments Covered | Product, Technology, Application, End User and Region |
| Key Companies Profiled | F.Hoffmann-La Roche Ltd.; Abbott Laboratories; Abaxis, Inc. (Sub of Zoetis Inc.); DiaSys Diagnostic Systems GmbH; ACON Laboratories; PTS Diagnostics; Bioptik Technology, Inc.; SD Biosensor, Inc.; Jant Pharmacal Corporation, Inc.; Nova Biomedical Corporation.; Beckman Coulter Inc. (Sub of Danaher Corporation); SAMSUNG HEALTH CARE, Inc. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The global point-of-care cholesterol monitoring device market is worth US$ 428.8 Mn in 2021 and is set to expand 1.2X over the forecasted years.
The sales of point-of-care cholesterol monitoring device in the market have grown at a CAGR of nearly 2.3% between 2013 and 2021.
The point-of-care cholesterol monitoring device market is expected to reach US$ 514.7 Mn by the end of 2028 with sales revenue expected to register CAGR of 2.6% over the forecast period.
North America is expected to dominate the global point-of-care cholesterol monitoring device market holding nearly 33.1% in 2022 of the global revenue share with U.S. being the leading contributor in this region having a market value of around US$ 126.2 Mn in 2022.
Demand of point-of-care cholesterol monitoring device market is expected to register growth in Asia Pacific at rate of 3.4% CAGR during the forecast period.
The point-of-care cholesterol monitoring device in China is likely to observe 1.3x growth during the forecast period with a growth rate of nearly 3.8% CAGR.
Increasing launch of new technological products, inclination towards portable devices, and increasing demand for home based testing for cholesterol are the key trends driving sales of point-of-care cholesterol monitoring device market across the globe.
India’s point-of-care cholesterol monitoring device market is offering lucrative growth opportunities and is expected to exhibit healthy growth of 3.0% CAGR during the forecast period. Japan market is expected to exhibit healthy growth of 3.0% CAGR during the forecast period.
U.S., China, Japan, Germany and U.K. are the top 5 countries that are driving the demand for point-of-care cholesterol monitoring device market.
Leading companies of Point-of-care Cholesterol Monitoring Device are F.Hoffmann-La, Roche Ltd., Abbott Laboratories, Abaxis, Inc. (Sub of Zoetis Inc.), DiaSys Diagnostic Systems GmbH, ACON Laboratories, PTS Diagnostics, Bioptik Technology, Inc., SD, Biosensor, Inc., Jant Pharmacal Corporation, Inc., Nova Biomedical Corporation., Beckman Coulter Inc. (Sub of Danaher Corporation) and SAMSUNG HEALTH CARE, Inc.
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Global Point of Care Cholesterol Monitoring Device Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. Global Economic Outlook
4.1. Global Gross Domestic Product by Region & Country, 2017 – 2022
5. Market Background
5.1. Market Evolution
5.2. Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Market Trends
6. Key Inclusions
6.1. Consumer Adoption Process
6.2. List of Manufacturers
6.3. Epidemiology Study
7. North America Point of Care Cholesterol Monitoring Device Market Analysis 2013-2021 and Forecast 2022-2028
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021
7.2.1. U.S.
7.2.2. Canada
7.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
7.4. Historical Market Value (US$ Mn) Analysis By Product, 2013-2021
7.4.1. Instruments
7.4.1.1. Table-top Analyzer
7.4.1.2. Hand-held Devices
7.4.2. Testing Kits
7.5. Market Value (US$ Mn) Forecast By Product, 2022-2028
7.6. Historical Market Value (US$ Mn) Analysis By Technology Type, 2013-2021
7.6.1. Electro chemical biosensor
7.6.2. Reflectance photometry
7.7. Market Value (US$ Mn) Forecast By Technology Type, 2022-2028
7.8. Historical Market Value (US$ Mn) Analysis By Application Type, 2013-2021
7.8.1. Dyslipidemia
7.8.2. Atherosclerosis
7.8.3. Hypercholesterolemia
7.8.4. Hypocholesterolemia
7.8.5. Others
7.9. Market Size (US$ Mn) Forecast By Application, 2022-2028
7.10. Market Size (US$ Mn) Forecast By End User, 2022-2028
7.11. Historical Market Value (US$ Mn) Analysis By End User, 2013-2021
7.11.1. Hospitals
7.11.2. Diagnostics centers & laboratory
7.11.3. Ambulatory surgical centers
7.11.4. Home care sittings
7.12. Market Size (US$ Mn) Forecast By End User, 2022-2028
7.13. Market Attractiveness Analysis
7.13.1. By Country
7.13.2. By Product
7.13.3. By Technology Type
7.13.4. By Application
7.13.5. By End User
7.14. Drivers and Restraints: Impact Analysis
7.15. Key Representative Participants Presence (Intensity Map)
8. Western Europe Point of Care Cholesterol Monitoring Device Market Analysis 2013-2021 and Forecast 2022-2028
8.1. Introduction
8.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021
8.2.1. Germany
8.2.2. U.K
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Western Europe
8.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
8.4. Historical Market Value (US$ Mn) Analysis By Product, 2013-2021
8.4.1. Instruments
8.4.1.1. Table-top Analyzer
8.4.1.2. Hand-held Devices
8.4.2. Testing Kits
8.5. Market Value (US$ Mn) Forecast By Product, 2022-2028
8.6. Historical Market Value (US$ Mn) Analysis By Technology Type, 2013-2021
8.6.1. Electro chemical biosensor
8.6.2. Reflectance photometry
8.7. Market Value (US$ Mn) Forecast By Technology Type, 2022-2028
8.8. Historical Market Value (US$ Mn) Analysis By Application Type, 2013-2021
8.8.1. Dyslipidemia
8.8.2. Atherosclerosis
8.8.3. Hypercholesterolemia
8.8.4. Hypocholesterolemia
8.8.5. Others
8.9. Market Size (US$ Mn) Forecast By Application, 2022-2028
8.10. Market Size (US$ Mn) Forecast By End User, 2022-2028
8.11. Historical Market Value (US$ Mn) Analysis By End User, 2013-2021
8.11.1. Hospitals
8.11.2. Diagnostics centers & laboratory
8.11.3. Ambulatory surgical centers
8.11.4. Home care sittings
8.12. Market Size (US$ Mn) Forecast By End User, 2022-2028
8.13. Market Attractiveness Analysis
8.13.1. By Country
8.13.2. By Product
8.13.3. By Technology Type
8.13.4. By Application
8.13.5. By End User
8.14. Drivers and Restraints: Impact Analysis
8.15. Key Representative Participants Presence (Intensity Map)
9. Eastern Europe Point of Care Cholesterol Monitoring Device Market Analysis 2013-2021 and Forecast 2022-2028
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021
9.2.1. Russia
9.2.2. Poland
9.2.3. Rest of Eastern Europe
9.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
9.4. Historical Market Value (US$ Mn) Analysis By Product, 2013-2021
9.4.1. Instruments
9.4.1.1. Table-top Analyzer
9.4.1.2. Hand-held Devices
9.4.2. Testing Kits
9.5. Market Value (US$ Mn) Forecast By Product, 2022-2028
9.6. Historical Market Value (US$ Mn) Analysis By Technology Type, 2013-2021
9.6.1. Electro chemical biosensor
9.6.2. Reflectance photometry
9.7. Market Value (US$ Mn) Forecast By Technology Type, 2022-2028
9.8. Historical Market Value (US$ Mn) Analysis By Application Type, 2013-2021
9.8.1. Dyslipidemia
9.8.2. Atherosclerosis
9.8.3. Hypercholesterolemia
9.8.4. Hypocholesterolemia
9.8.5. Others
9.9. Market Size (US$ Mn) Forecast By Application, 2022-2028
9.10. Market Size (US$ Mn) Forecast By End User, 2022-2028
9.11. Historical Market Value (US$ Mn) Analysis By End User, 2013-2021
9.11.1. Hospitals
9.11.2. Diagnostics centers & laboratory
9.11.3. Ambulatory surgical centers
9.11.4. Home care sittings
9.12. Market Size (US$ Mn) Forecast By End User, 2022-2028
9.13. Market Attractiveness Analysis
9.13.1. By Country
9.13.2. By Product
9.13.3. By Technology Type
9.13.4. By Application
9.13.5. By End User
9.14. Drivers and Restraints: Impact Analysis
9.15. Key Representative Participants Presence (Intensity Map)
10. Latin America Point of Care Cholesterol Monitoring Device Market Analysis 2013-2021 and Forecast 2022-2028
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021
10.3. Brazil
10.3.1. Mexico
10.3.2. Rest of Latin America
10.4. Market Size (US$ Mn) Forecast By Country, 2022-2028
10.5. Historical Market Value (US$ Mn) Analysis By Product, 2013-2021
10.5.1. Instruments
10.5.1.1. Table-top Analyzer
10.5.1.2. Hand-held Devices
10.5.2. Testing Kits
10.6. Market Value (US$ Mn) Forecast By Product, 2022-2028
10.7. Historical Market Value (US$ Mn) Analysis By Technology Type, 2013-2021
10.7.1. Electro chemical biosensor
10.7.2. Reflectance photometry
10.8. Market Value (US$ Mn) Forecast By Technology Type, 2022-2028
10.9. Historical Market Value (US$ Mn) Analysis By Application Type, 2013-2021
10.9.1. Dyslipidemia
10.9.2. Atherosclerosis
10.9.3. Hypercholesterolemia
10.9.4. Hypocholesterolemia
10.9.5. Others
10.10. Market Size (US$ Mn) Forecast By Application, 2022-2028
10.11. Market Size (US$ Mn) Forecast By End User, 2022-2028
10.12. Historical Market Value (US$ Mn) Analysis By End User, 2013-2021
10.12.1. Hospitals
10.12.2. Diagnostics centers & laboratory
10.12.3. Ambulatory surgical centers
10.12.4. Home care sittings
10.13. Market Size (US$ Mn) Forecast By End User, 2022-2028
10.14. Market Attractiveness Analysis
10.14.1. By Country
10.14.2. By Product
10.14.3. By Technology Type
10.14.4. By Application
10.14.5. By End User
10.15. Drivers and Restraints: Impact Analysis
10.16. Key Representative Participants Presence (Intensity Map)
11. Asia-Pacific Excluding Japan Point of Care Cholesterol Monitoring Device Market Analysis 2013-2021 and Forecast 2022-2028
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021
11.2.1. China
11.2.2. India
11.2.3. Australia and New Zealand
11.2.4. ASEAN
11.2.5. Rest of APEJ
11.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
11.4. Historical Market Value (US$ Mn) Analysis By Product, 2013-2021
11.4.1. Instruments
11.4.1.1.1. Table-top Analyzer
11.4.1.1.2. Hand-held Devices
11.4.2. Testing Kits
11.5. Market Value (US$ Mn) Forecast By Product, 2022-2028
11.6. Historical Market Value (US$ Mn) Analysis By Technology Type, 2013-2021
11.6.1. Electro chemical biosensor
11.6.2. Reflectance photometry
11.7. Market Value (US$ Mn) Forecast By Technology Type, 2022-2028
11.8. Historical Market Value (US$ Mn) Analysis By Application Type, 2013-2021
11.8.1. Dyslipidemia
11.8.2. Atherosclerosis
11.8.3. Hypercholesterolemia
11.8.4. Hypocholesterolemia
11.8.5. Others
11.9. Market Size (US$ Mn) Forecast By Application, 2022-2028
11.10. Market Size (US$ Mn) Forecast By End User, 2022-2028
11.11. Historical Market Value (US$ Mn) Analysis By End User, 2013-2021
11.11.1. Hospitals
11.11.2. Diagnostics centers & laboratory
11.11.3. Ambulatory surgical centers
11.11.4. Home care sittings
11.12. Market Size (US$ Mn) Forecast By End User, 2022-2028
11.13. Market Attractiveness Analysis
11.13.1. By Country
11.13.2. By Product
11.13.3. By Technology Type
11.13.4. By Application
11.13.5. By End User
11.14. Drivers and Restraints: Impact Analysis
11.15. Key Representative Participants Presence (Intensity Map)
12. Japan Point of Care Cholesterol Monitoring Device Market Analysis 2013-2021 and Forecast 2022-2028
12.1. Introduction
12.2. Market Size (US$ Mn) Forecast By Country, 2022-2028
12.3. Historical Market Value (US$ Mn) Analysis By Product, 2013-2021
12.3.1. Instruments
12.3.1.1. Table-top Analyzer
12.3.1.2. Hand-held Devices
12.3.2. Testing Kits
12.4. Market Value (US$ Mn) Forecast By Product, 2022-2028
12.5. Historical Market Value (US$ Mn) Analysis By Technology Type, 2013-2021
12.5.1. Electro chemical biosensor
12.5.2. Reflectance photometry
12.6. Market Value (US$ Mn) Forecast By Technology Type, 2022-2028
12.7. Historical Market Value (US$ Mn) Analysis By Application Type, 2013-2021
12.7.1. Dyslipidemia
12.7.2. Atherosclerosis
12.7.3. Hypercholesterolemia
12.7.4. Hypocholesterolemia
12.7.5. Others
12.8. Market Size (US$ Mn) Forecast By Application, 2022-2028
12.9. Market Size (US$ Mn) Forecast By End User, 2022-2028
12.10. Historical Market Value (US$ Mn) Analysis By End User, 2013-2021
12.10.1. Hospitals
12.10.2. Diagnostics centers & laboratory
12.10.3. Ambulatory surgical centers
12.10.4. Home care sittings
12.11. Market Size (US$ Mn) Forecast By End User, 2022-2028
12.12. Market Attractiveness Analysis
12.12.1. By Country
12.12.2. By Product
12.12.3. By Technology Type
12.12.4. By Modality Type
12.12.5. By Application
12.12.6. By End User
12.13. Drivers and Restraints: Impact Analysis
12.14. Key Representative Participants Presence (Intensity Map)
13. Middle East and Africa Point of Care Cholesterol Monitoring Device Market Analysis 2013-2021 and Forecast 2022-2028
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021
13.2.1. GCC Countries
13.2.2. South Africa
13.2.3. Rest of MEA
13.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
13.4. Historical Market Value (US$ Mn) Analysis By Product, 2013-2021
13.4.1. Instruments
13.4.1.1.1. Table-top Analyzer
13.4.1.1.2. Hand-held Devices
13.4.2. Testing Kits
13.5. Market Value (US$ Mn) Forecast By Product, 2022-2028
13.6. Historical Market Value (US$ Mn) Analysis By Technology Type, 2013-2021
13.6.1. Electro chemical biosensor
13.6.2. Reflectance photometry
13.7. Market Value (US$ Mn) Forecast By Technology Type, 2022-2028
13.8. Historical Market Value (US$ Mn) Analysis By Application Type, 2013-2021
13.8.1. Dyslipidemia
13.8.2. Atherosclerosis
13.8.3. Hypercholesterolemia
13.8.4. Hypocholesterolemia
13.8.5. Others
13.9. Market Size (US$ Mn) Forecast By Application, 2022-2028
13.10. Market Size (US$ Mn) Forecast By End User, 2022-2028
13.11. Historical Market Value (US$ Mn) Analysis By End User, 2013-2021
13.11.1. Hospitals
13.11.2. Diagnostics centers & laboratory
13.11.3. Ambulatory surgical centers
13.11.4. Home care sittings
13.12. Market Size (US$ Mn) Forecast By End User, 2022-2028
13.13. Market Attractiveness Analysis
13.13.1. By Country
13.13.2. By Product
13.13.3. By Technology Type
13.13.4. By Application
13.13.5. By End User
13.14. Drivers and Restraints: Impact Analysis
13.15. Key Representative Participants Presence (Intensity Map)
14. Forecast Factors: Relevance and Impact
15. Forecast Assumptions
16. Competition Analysis
16.1. Competition Dashboard
16.2. Competitors Deep Dive
16.2.1. ACON Laboratories, Inc.
16.2.1.1. Overview
16.2.1.2. Product and Modality Portfolio
16.2.1.3. Production Footprint
16.2.1.4. Sales Footprint
16.2.1.5. Channel Footprint
16.2.1.6. Strategy
16.2.1.6.1. Marketing Strategy
16.2.1.6.2. Product Strategy
16.2.1.6.3. Channel Strategy
16.2.2. DiaSys Diagnostic Systems GmbH.
16.2.2.1. Overview
16.2.2.2. Product and Modality Portfolio
16.2.2.3. Production Footprint
16.2.2.4. Sales Footprint
16.2.2.5. Channel Footprint
16.2.2.6. Strategy
16.2.2.6.1. Marketing Strategy
16.2.2.6.2. Product Strategy
16.2.2.6.3. Channel Strategy
16.2.3. Roche Diagnostics
16.2.3.1. Overview
16.2.3.2. Product and Modality Portfolio
16.2.3.3. Production Footprint
16.2.3.4. Sales Footprint
16.2.3.5. Channel Footprint
16.2.3.6. Strategy
16.2.3.6.1. Marketing Strategy
16.2.3.6.2. Product Strategy
16.2.3.6.3. Channel Strategy
16.2.4. Home Health Ltd.
16.2.4.1. Overview
16.2.4.2. Product and Modality Portfolio
16.2.4.3. Production Footprint
16.2.4.4. Sales Footprint
16.2.4.5. Channel Footprint
16.2.4.6. Strategy
16.2.4.6.1. Marketing Strategy
16.2.4.6.2. Product Strategy
16.2.4.6.3. Channel Strategy
16.2.5. SD Biosensor, INC
16.2.5.1. Overview
16.2.5.2. Product and Modality Portfolio
16.2.5.3. Production Footprint
16.2.5.4. Sales Footprint
16.2.5.5. Channel Footprint
16.2.5.6. Strategy
16.2.5.6.1. Marketing Strategy
16.2.5.6.2. Product Strategy
16.2.5.6.3. Channel Strategy
16.2.6. Alere Inc.
16.2.6.1. Overview
16.2.6.2. Product and Modality Portfolio
16.2.6.3. Production Footprint
16.2.6.4. Sales Footprint
16.2.6.5. Channel Footprint
16.2.6.6. Strategy
16.2.6.6.1. Marketing Strategy
16.2.6.6.2. Product Strategy
16.2.6.6.3. Channel Strategy
16.2.7. Abaxis Inc.
16.2.7.1. Overview
16.2.7.2. Product and Modality Portfolio
16.2.7.3. Production Footprint
16.2.7.4. Sales Footprint
16.2.7.5. Channel Footprint
16.2.7.6. Strategy
16.2.7.6.1. Marketing Strategy
16.2.7.6.2. Product Strategy
16.2.7.6.3. Channel Strategy
16.2.8. Polymer Technology Systems, Inc.
16.2.8.1. Overview
16.2.8.2. Product and Modality Portfolio
16.2.8.3. Production Footprint
16.2.8.4. Sales Footprint
16.2.8.5. Channel Footprint
16.2.8.6. Strategy
16.2.8.6.1. Marketing Strategy
16.2.8.6.2. Product Strategy
16.2.8.6.3. Channel Strategy
16.2.9. BIOPTIK LTD.
16.2.9.1. Overview
16.2.9.2. Product and Modality Portfolio
16.2.9.3. Production Footprint
16.2.9.4. Sales Footprint
16.2.9.5. Channel Footprint
16.2.9.6. Strategy
16.2.9.6.1. Marketing Strategy
16.2.9.6.2. Product Strategy
16.2.9.6.3. Channel Strategy
16.2.10. OSANG HEALTHCARE CO., LTD.
16.2.10.1. Overview
16.2.10.2. Product and Modality Portfolio
16.2.10.3. Production Footprint
16.2.10.4. Sales Footprint
16.2.10.5. Channel Footprint
16.2.10.6. Strategy
16.2.10.6.1. Marketing Strategy
16.2.10.6.2. Product Strategy
16.2.10.6.3. Channel Strategy
16.2.11. Fitech UK Ltd,
16.2.11.1. Overview
16.2.11.2. Product and Modality Portfolio
16.2.11.3. Production Footprint
16.2.11.4. Sales Footprint
16.2.11.5. Channel Footprint
16.2.11.6. Strategy
16.2.11.6.1. Marketing Strategy
16.2.11.6.2. Product Strategy
16.2.11.6.3. Channel Strategy
16.2.12. PRIMA Lab SA
16.2.12.1. Overview
16.2.12.2. Product and Modality Portfolio
16.2.12.3. Production Footprint
16.2.12.4. Sales Footprint
16.2.12.5. Channel Footprint
16.2.12.6. Strategy
16.2.12.6.1. Marketing Strategy
16.2.12.6.2. Product Strategy
16.2.12.6.3. Channel Strategy
16.2.13. Chematics, Inc.
16.2.13.1. Overview
16.2.13.2. Product and Modality Portfolio
16.2.13.3. Production Footprint
16.2.13.4. Sales Footprint
16.2.13.5. Channel Footprint
16.2.13.6. Strategy
16.2.13.6.1. Marketing Strategy
16.2.13.6.2. Product Strategy
16.2.13.6.3. Channel Strategy
16.2.14. Solana Health Inc.
16.2.14.1. Overview
16.2.14.2. Product and Modality Portfolio
16.2.14.3. Production Footprint
16.2.14.4. Sales Footprint
16.2.14.5. Channel Footprint
16.2.14.6. Strategy
16.2.14.6.1. Marketing Strategy
16.2.14.6.2. Product Strategy
16.2.14.6.3. Channel Strategy
16.2.15. AccuTech, LLC
16.2.15.1. Overview
16.2.15.2. Product and Modality Portfolio
16.2.15.3. Production Footprint
16.2.15.4. Sales Footprint
16.2.15.5. Channel Footprint
16.2.15.6. Strategy
16.2.15.6.1. Marketing Strategy
16.2.15.6.2. Product Strategy
16.2.15.6.3. Channel Strategy
Explore Healthcare Insights
View Reports
Point-of-care Cholesterol Monitoring Device Market
